Literature DB >> 31231902

Increasing phenotypic annotation improves the diagnostic rate of exome sequencing in a rare neuromuscular disorder.

Rachel Thompson1, Anastasios Papakonstantinou Ntalis2, Sergi Beltran2,3, Ana Töpf1, Eduardo de Paula Estephan4, Kiran Polavarapu5, Peter A C 't Hoen6, Paolo Missier7, Hanns Lochmüller2,8,9,10.   

Abstract

Phenotype-based filtering and prioritization contribute to the interpretation of genetic variants detected in exome sequencing. However, it is currently unclear how extensive this phenotypic annotation should be. In this study, we compare methods for incorporating phenotype into the interpretation process and assess the extent to which phenotypic annotation aids prioritization of the correct variant. Using a cohort of 29 patients with congenital myasthenic syndromes with causative variants in known or newly discovered disease genes, exome data and the Human Phenotype Ontology (HPO)-coded phenotypic profiles, we show that gene-list filters created from phenotypic annotations perform similarly to curated disease-gene virtual panels. We use Exomiser, a prioritization tool incorporating phenotypic comparisons, to rank candidate variants while varying phenotypic annotation. Analyzing 3,712 combinations, we show that increasing phenotypic annotation improved prioritization of the causative variant, from 62% ranked first on variant alone to 90% with seven HPO annotations. We conclude that any HPO-based phenotypic annotation aids variant discovery and that annotation with over five terms is recommended in our context. Although focused on a constrained cohort, this provides real-world validation of the utility of phenotypic annotation for variant prioritization. Further research is needed to extend this concept to other diseases and more diverse cohorts.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Exomiser; congenital myasthenic syndromes; deep phenotyping; diagnosis; exome sequencing; human phenotype ontology; variant prioritization

Mesh:

Year:  2019        PMID: 31231902     DOI: 10.1002/humu.23792

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  8 in total

Review 1.  Phenotype-driven approaches to enhance variant prioritization and diagnosis of rare disease.

Authors:  Julius O B Jacobsen; Catherine Kelly; Valentina Cipriani; Genomics England Research Consortium; Christopher J Mungall; Justin Reese; Daniel Danis; Peter N Robinson; Damian Smedley
Journal:  Hum Mutat       Date:  2022-04-27       Impact factor: 4.700

2.  Diagnostic yield and clinical utility of whole exome sequencing using an automated variant prioritization system, EVIDENCE.

Authors:  Go Hun Seo; Taeho Kim; In Hee Choi; Jung-Young Park; Jungsul Lee; Sehwan Kim; Dhong-Gun Won; Arum Oh; Yena Lee; Jeongmin Choi; Hajeong Lee; Hee Gyung Kang; Hee Yeon Cho; Min Hyun Cho; Yoon Jeon Kim; Young Hee Yoon; Baik-Lin Eun; Robert J Desnick; Changwon Keum; Beom Hee Lee
Journal:  Clin Genet       Date:  2020-09-17       Impact factor: 4.438

3.  The Human Phenotype Ontology in 2021.

Authors:  Sebastian Köhler; Michael Gargano; Nicolas Matentzoglu; Leigh C Carmody; David Lewis-Smith; Nicole A Vasilevsky; Daniel Danis; Ganna Balagura; Gareth Baynam; Amy M Brower; Tiffany J Callahan; Christopher G Chute; Johanna L Est; Peter D Galer; Shiva Ganesan; Matthias Griese; Matthias Haimel; Julia Pazmandi; Marc Hanauer; Nomi L Harris; Michael J Hartnett; Maximilian Hastreiter; Fabian Hauck; Yongqun He; Tim Jeske; Hugh Kearney; Gerhard Kindle; Christoph Klein; Katrin Knoflach; Roland Krause; David Lagorce; Julie A McMurry; Jillian A Miller; Monica C Munoz-Torres; Rebecca L Peters; Christina K Rapp; Ana M Rath; Shahmir A Rind; Avi Z Rosenberg; Michael M Segal; Markus G Seidel; Damian Smedley; Tomer Talmy; Yarlalu Thomas; Samuel A Wiafe; Julie Xian; Zafer Yüksel; Ingo Helbig; Christopher J Mungall; Melissa A Haendel; Peter N Robinson
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

4.  Outlier concepts auditing methodology for a large family of biomedical ontologies.

Authors:  Ling Zheng; Hua Min; Yan Chen; Vipina Keloth; James Geller; Yehoshua Perl; George Hripcsak
Journal:  BMC Med Inform Decis Mak       Date:  2020-12-15       Impact factor: 2.796

Review 5.  The Increasing Impact of Translational Research in the Molecular Diagnostics of Neuromuscular Diseases.

Authors:  Dèlia Yubero; Daniel Natera-de Benito; Jordi Pijuan; Judith Armstrong; Loreto Martorell; Guerau Fernàndez; Joan Maynou; Cristina Jou; Mònica Roldan; Carlos Ortez; Andrés Nascimento; Janet Hoenicka; Francesc Palau
Journal:  Int J Mol Sci       Date:  2021-04-20       Impact factor: 5.923

Review 6.  Added Value of Reanalysis of Whole Exome- and Whole Genome Sequencing Data From Patients Suspected of Primary Immune Deficiency Using an Extended Gene Panel and Structural Variation Calling.

Authors:  Sara Bohnstedt Mørup; Lusine Nazaryan-Petersen; Migle Gabrielaite; Joanne Reekie; Hanne V Marquart; Hans Jakob Hartling; Rasmus L Marvig; Terese L Katzenstein; Tania N Masmas; Jens Lundgren; Daniel D Murray; Marie Helleberg; Line Borgwardt
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

7.  Systematic use of phenotype evidence in clinical genetic testing reduces the frequency of variants of uncertain significance.

Authors:  Britt Johnson; Karen Ouyang; Lauren Frank; Rebecca Truty; Susan Rojahn; Ana Morales; Swaroop Aradhya; Keith Nykamp
Journal:  Am J Med Genet A       Date:  2022-05-16       Impact factor: 2.578

8.  Solving patients with rare diseases through programmatic reanalysis of genome-phenome data.

Authors:  Leslie Matalonga; Carles Hernández-Ferrer; Davide Piscia; Rebecca Schüle; Matthis Synofzik; Ana Töpf; Lisenka E L M Vissers; Richarda de Voer; Raul Tonda; Steven Laurie; Marcos Fernandez-Callejo; Daniel Picó; Carles Garcia-Linares; Anastasios Papakonstantinou; Alberto Corvó; Ricky Joshi; Hector Diez; Ivo Gut; Alexander Hoischen; Holm Graessner; Sergi Beltran
Journal:  Eur J Hum Genet       Date:  2021-06-01       Impact factor: 4.246

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.